Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

41. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial (Abstract)

Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial Individual gut-directed hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FAP[S]). It is, however, unavailable to many children.To compare the effectiveness of HT by means

2017 EvidenceUpdates

42. Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop Full Text available with Trip Pro

Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop A working theoretical model for irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGIDs) does not exist, hampered by the lack of any clear cut invention that address all symptom and signs of the disease. Reports of cessation of symptom and signs of both major types

2017 Translational gastroenterology and hepatology

43. The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. Full Text available with Trip Pro

The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. Hypnotherapy has been reported as being beneficial in the treatment of irritable bowel syndrome (IBS). We aimed to test the hypothesis that patients with IBS treated 'holistically' by hypnosis (i.e. by combined psychological and physiological symptom imagery) would have greater improvement in their IBS symptoms than patients treated by hypnosis using standard 'gut-directed (...) ' hypnotherapy, and both would be superior to simple relaxation therapy.Patients (n = 51) with Rome II criteria were randomised to 'individualised' (holistic) hypnotherapy, standard 'gut-directed' hypnotherapy or relaxation therapy for a period of 11 weeks with two follow-up assessments at 2 weeks and at 3 months after the completion of the trial. The primary outcome was bowel symptom severity scale (BSSS).All the participants in this study improved their IBS symptoms (pain, bloating, constipation

2017 Health psychology open Controlled trial quality: uncertain

47. Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea

index BSS Bristol Stool Scale CHMP Committee for Medicinal Products for Human Use Cmax maximum observed plasma concentration CNS central nervous system CSR clinical study report EMA European Medicines Agency EU European Union FDA US Food and Drug Administration GERD gastroesophageal reflux disease GI gastrointestinal IBS irritable bowel syndrome IBS-d diarrhea-predominant irritable bowel syndrome IBS-m irritable bowel syndrome, where a mixture of constipation and diarrhea is predominant IBS-QoL (...) discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Truberzi. Assessment report EMA/549473/2016 Page 8/108 2. Scientific discussion 2.1. Introduction Problem statement Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal problem characterised primarily by intestinal pain and/or discomfort and associated alterations of defecation and/or bowel habit. Associations with other symptoms are regularly present, such as abdominal distension

2016 European Medicines Agency - EPARs

48. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women Full Text available with Trip Pro

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron (...) consistency (40.8%; 95% CI, 35.1%-46.6%) than in the placebo group (24.3%; 95% CI, 19.4%-29.7%)--a difference of 16.5% (95% CI, 8.9%-24.0%; P < .001). Patients receiving ramosetron had significant reductions in abdominal pain and discomfort (P = .001) and greater improvement in QOL (P = .002) compared with placebo. Ramosetron induced constipation in 11.0% of patients.In a randomized, placebo-controlled study of 576 women with IBS-D, 2.5 μg ramosetron per day reduced symptoms and increased stool

2016 EvidenceUpdates Controlled trial quality: predicted high

49. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Full Text available with Trip Pro

Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Irritable bowel syndrome (IBS) affects a large number of children throughout the world. The symptom expression of IBS is heterogeneous, and several factors which may be interrelated within the IBS biopsychosocial model play a role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut inflammation, bile acids, food intolerance, colonic bacterial

2016 Molecular and cellular pediatrics

50. Genetics of irritable bowel syndrome Full Text available with Trip Pro

Genetics of irritable bowel syndrome Irritable bowel syndrome (IBS) is a common condition with a complex and largely unknown etiology. There is no cure, and treatment options are mainly directed to the amelioration of symptoms. IBS causes reduced quality of life and poses considerable repercussions on health and socioeconomic systems. There is a heritable component in IBS, and genetic research is a valuable tool for the identification of causative pathways, which will provide important insight (...) into the pathophysiology. However, although some gene-hunting efforts have been conducted and a few risk genes proposed, IBS genetic research is lagging behind compared to other complex diseases. In this mini-review, we briefly summarize existing genetic studies, discuss the main challenges in IBS genetic research, and propose strategies to overcome these challenges for IBS gene discovery.

2016 Molecular and cellular pediatrics

51. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Full Text available with Trip Pro

Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist), in patients with IBS with diarrhea. Methods We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose (...) of 75 mg or 100 mg) or placebo twice daily for 26 weeks (IBS-3002 trial) or 52 weeks (IBS-3001 trial). The primary end point was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of the days from weeks 1 through 12 and from weeks 1 through 26. Results For weeks 1 through 12, more patients in the eluxadoline groups (75 mg and 100 mg) than in the placebo group reached the primary end point (IBS

2016 NEJM Controlled trial quality: predicted high

52. Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial Full Text available with Trip Pro

Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial A diet with reduced content of fermentable short-chain carbohydrates (fermentable oligo-, di-, monosaccharides, and polyols [FODMAPs]) has been reported to be effective in the treatment of patients with irritable bowel syndrome (IBS). However, there is no evidence of its superiority to traditional dietary advice for these patients. We compared the effects (...) of a diet low in FODMAPs with traditional dietary advice in a randomized controlled trial of patients with IBS.We performed a multi-center, parallel, single-blind study of 75 patients who met Rome III criteria for IBS and were enrolled at gastroenterology outpatient clinics in Sweden. Subjects were randomly assigned to groups that ate specific diets for 4 weeks-a diet low in FODMAPs (n = 38) or a diet frequently recommended for patients with IBS (ie, a regular meal pattern; avoidance of large meals

2016 EvidenceUpdates Controlled trial quality: uncertain

53. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines

syndrome? What are the evidence-based guidelines for the use of trimebutine maleate and pinaverium bromide for the treatment of irritable bowel syndrome? Key Message Evidence suggests that compared with placebo there may be improvement in abdominal pain with trimebutine or pinaverium treatment for adult patients with irritable bowel syndrome (IBS), however results were not always statistically significant. Findings from single RCTs suggest improvement in stool consistency and frequency with trimebutine (...) or pinaverium treatment. Adverse effects with trimebutine or pinavarium appeared to be few, however not many studies reported on adverse effects. No evidence-based guidelines were identified for the use of trimebutine and pinaverium for the treatment of irritable bowel syndrome. Tags gastrointestinal tract, irritable bowel syndrome Files Rapid Response Summary with Critical Appraisal Published : November 30, 2015 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

54. Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Full Text available with Trip Pro

Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in children. Recently, probiotics have been suggested as a treatment option for gastrointestinal disorders. The most effective species and the most appropriate doses are still unknown.The aim of this study was to assess the effects of Lactobacillus GG (LGG) for treating IBS in pediatric patients.In a controlled, double blind (...) one, two, three, and four weeks of treatment, as indicated by P-values of 0.01, 0.00, 0.00, and 0.00, respectively. Also, there was significant improvement in the functional scale after two weeks of treatment (P-value ≤ 0.00).Lactobacillus GG at a concentration of 1×10(10) cfu/ml for a period of four weeks can lessen the severity of the patients' pain and improve the functional scale in patients with irritable bowel syndrome. Probiotics can have therapeutic effects for IBS patients.

2015 Electronic physician Controlled trial quality: predicted high

55. Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what?

Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what? 2015. DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation DAR No 4: Linaclotide. Constella (...) ® in the symptomatic management of irritable bowel syndrome with constipation Content tools Share it The indication was granted...so what? Although authorized for irritable bowel syndrome with constipation it offers only symptomatic relief. In the best of cases, one in five patients can benefit from treatment. On the other hand, one in five patients can suffer from diarrhea as a secondary effect which can last for more than 28 days in half the cases. There are no available studies evaluating

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

56. Irritable bowel syndrome: new and emerging treatments. Full Text available with Trip Pro

Irritable bowel syndrome: new and emerging treatments. Irritable bowel syndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target the peripheral gastrointestinal system and central nervous system, are used to treat the syndrome. The individual and societal impact of investigating and managing the syndrome is substantial (...) , and despite newer treatments, many patients have unmet needs. Intense research at many international sites has improved the understanding of pathophysiology of the syndrome, but developing treatments that are effective, safe, and that have tolerable side effects remains a challenge. This review briefly summarizes the currently available treatments for irritable bowel syndrome then focuses on newer non-pharmacological and pharmacological therapies and recent evidence for older treatments. Recent guidelines

2015 BMJ

57. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Full Text available with Trip Pro

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try

2015 NIHR HTA programme

58. An antiemetic for irritable bowel syndrome?

An antiemetic for irritable bowel syndrome? An antiemetic for irritable bowel syndrome? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics An antiemetic for irritable bowel syndrome? View/ Open Date 2014-10 Format Metadata Abstract An antiemetic for irritable bowel syndrome? A drug used for cancer patients may provide (...) some relief to patients with IBS. Practice changer: Consider prescribing ondansetron up to 24 mg/d for patients who have irritable bowel syndrome with diarrhea (IBS-D). URI Part of Citation Journal of Family Practice, 63(10) 2014: 600-602. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2015 PURLS

59. Viberzi (eluxadoline) - To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women

Viberzi (eluxadoline) - To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women Viberzi (eluxadoline) Tablets U.S. Department of Health and Human Services Search FDA Submit search Viberzi (eluxadoline) Tablets Viberzi (eluxadoline) Tablet Company: Furiex Pharmaceuticals, Inc. Application No.: 206940 Approval Date: 05/27/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

60. Qualitative study?other: Uncovering male and female experiences of irritable bowel syndrome

Commentary on : Bjorkman I , Dellenborg L , Ringstrom G , et al . The gendered impact of irritable bowel syndrome: a qualitative study of patients’ experiences . Implications for practice and research A more gender sensitive approach in the healthcare setting could increase understanding of patients’ experience of irritable bowel syndrome (IBS). Intervention studies from a person centred, gender-sensitive perspective should be conducted. Context IBS is a common, chronic functional bowel disorder (...) Qualitative study?other: Uncovering male and female experiences of irritable bowel syndrome Uncovering male and female experiences of irritable bowel syndrome | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts

2015 Evidence-Based Nursing